Dr. Reddy's Lab reports positive topline results from Phase 2b study of PPC-06

10 Jun 2019 Evaluate

Dr. Reddy's Laboratories has reported positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis. In the study, PPC-06 met both co-primary endpoints i.e. PASI- 75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks of oral treatment.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1321.50 7.60 (0.58%)
11-Mar-2026 09:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.45
Dr. Reddys Lab 1321.50
Cipla 1329.20
Zydus Lifesciences 932.00
Lupin 2351.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×